阿诺医药 ANL 深 沪
交易中 08-25 10:26:53 美东时间
14.195
+0.035
+0.25%
华盛通- 最 高14.29
- 今 开14.09
- 成交量 7640股
- 最 低 13.86
- 昨 收 14.16
- 总市值 9.14亿
- 52周最高 17.25
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.8786
- 委 比 24.81%
- 总股本 6439.79万
- 历史最高 19.2999
- 量 比 0.49
- 振 幅 3.04%
- 历史最低 0.8786
- 每 手 1
- 风险率 5.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has issued an update. On July 29, 20...
08-19 20:57
Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M
Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year. The company reported $13.056 million in sales this quarter.
08-14 19:22
Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Adl...
08-03 19:04
奥赛康：泛RAS(ON)分子胶ASKC189全球I期临床试验完成间歇给药方案首例患者入组
7月16日，奥赛康（002755.SZ）宣布，泛 RAS（ON）分子胶 ASKC189全球一期临床试验再获关键进展： 该 I 期研究已于今年2月完成标准每日一次...
07-17 11:24
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday. Shares of Concentrix Corp (NASDAQ:CNXC) fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY26 guidance below estima...
06-30 20:03
Cantor Fitzgerald Initiates Coverage On Adlai Nortye with Overweight Rating
Cantor Fitzgerald analyst Li Watsek initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Overweight rating.
06-22 21:20
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Oppenheimer Initiates Coverage On Adlai Nortye with Outperform Rating, Announces Price Target of $32
Oppenheimer analyst Jay Olson initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Outperform rating and announces Price Target of $32.
05-29 01:59
